摘要
目的探讨肺炎支原体(MP)感染诱发的儿童哮喘急性期应用布地奈德雾化吸入治疗的临床效果及其对患儿体内炎症因子水平的影响,旨在为该病的临床治疗提供参考依据。方法选取228例确诊为MP感染但住院时尚未出现喘息的既往哮喘患儿为研究对象,根据随机数字表将患儿分为布地奈德雾化吸入治疗组(观察组)113例以及常规治疗组(对照组)115例,对比分析两种治疗方法对患儿肺功能、临床症状以及炎症因子水平的影响。结果观察组患儿吸气的容积(FEV1)、呼气峰流速(PEF)、第1秒呼吸气体的容积与用力肺活量的比值(FEV1/FVC)分别为(91.42±6.50)%、(96.80±14.32)%、82.40±5.21显著高于对照组FEV1(68.98±6.41)%、PEF(71.25±12.58)%、FEV1/FVC 72.35±5.42,差异有统计学意义(P<0.05);观察组患儿呼吸困难、咳嗽、肺部啰音等临床症状改善时间显著优于对照组,差异有统计学意义(P<0.05);观察组肿瘤坏死因子(TNF-A)、白细胞介素6、8(IL-6、IL-8)等炎症因子水平分别为(221.4±33.5)、(145.5±31.2)、(78.5±19.6)ng/L,显著低于对照组的(385.5±31.2)、(217.4±38.5)、(105.4±22.8)ng/L,差异有统计学意义(P<0.05)。结论布地奈德雾化吸入能有效改善患儿肺功能以及临床症状,同时能降低患儿炎症因子水平,对预防MP感染诱发的儿童急性哮喘发作具有重要的作用。
OBJECTIVE To investigate the effect of budesonide inhalation on Mycoplasma pneumoniae （MP） infection-induced asthma in children and its impact on the levels of inflammatory factors in vivo, so as to provide basis for the clinical treatment. METHODS A total of 228 cases of asthma chindren with confirmed MP infection but not with gasping symptoms were collected as the research subjects and randomly divided into budesonide inhalation treatment group （observation group）（113 cases） and conventional treatment group （control group）（ 115 cases）. The effects of the two therapeutic methods on lung function, clinical symptoms and inflammatory factor levels were analyzed. RESULTS Forced expiratory volume （FEV1. 0） （91. 42± 6. 50）, peak expiratory flow （PEF） （96. 80±14.32）, the first second forced expiratory volume and forced vital capacity ratio （FEV1.0/FVC） （82.40± 5. 21） of observation group were significantly higher than those of control group （（68. 98 ±6.41）, （71.25±12.58）, （72.35±5.42） respectively）, and the differences were significant （P〈0.05）. The improving of clinical symptoms including difficulty in breathing, coughing, pulmonary rale of observation group was significantly better than that of the control group （P 〈0.05）. The levels of inflammatory factors including tumor necrosis factor （TNF-A）, interleukin 6,8 （IL-6, IL-8） of Observation group（（221.4± 33. 5） ng/L, （145. 5 ±31.2） ng/L, （78. 5 ± 19. 6） ng/L respectively） were significantly lower than those of control group （385.5 ±31.2） ng/L, （217.4±38.5） ng/L （105.4±22.8） ng/L respectively） （P〈0.05）. CONCLUSION Budesonide inhalation can effectively improve lung function and clinical symptoms, and reduce the levels of inflammatory factors. It plays a great role in the prevention of MP infection-induced acute attack of asthma.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2014年第11期2829-2831,共3页
Chinese Journal of Nosocomiology
基金
湖州市科技局基金资助项目(2011YS03)
关键词
布地奈德
肺炎支原体
儿童哮喘
Budesonide
Mycoplasma pneumoniae
asthma in children
